These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1166858)

  • 21. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus.
    Jones JV; Cumming RH; Bacon PA; Evers J; Fraser ID; Bothamley J; Tribe CR; Davis P; Hughes GR
    Q J Med; 1979 Oct; 48(192):555-76. PubMed ID: 317156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D; Williams DG
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus.
    Park YB; Lee SK; Kim DS; Lee J; Lee CH; Song CH
    Clin Exp Rheumatol; 1998; 16(3):283-8. PubMed ID: 9631750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis.
    Adu D; Williams DG; Taube D; Vilches AR; Turner DR; Cameron JS; Ogg CS
    Q J Med; 1983; 52(208):471-87. PubMed ID: 6606818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlations between anti-dsDNA antibodies, complement levels and clinical course in SLE patients treated with steroid pulse therapy.
    Pioltelli P; Procaccio F; Invernizzi F; Ponticelli C; Tarantino A
    Boll Ist Sieroter Milan; 1978 Sep; 57(4):485-9. PubMed ID: 737041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-reactive protein and serological indices of disease activity in systemic lupus erythematosus.
    Bertouch JV; Roberts-Thompson PJ; Feng PH; Bradley J
    Ann Rheum Dis; 1983 Dec; 42(6):655-8. PubMed ID: 6606401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum immune complexes in membranoproliferative and other glomerulonephritides.
    Ooi YM; Vallota EH; West CD
    Kidney Int; 1977 Apr; 11(4):275-83. PubMed ID: 853604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/anti-DNA antibody immune complexes.
    Morimoto C; Sano H; Abe T; Homma M; Steinberg AD
    J Immunol; 1982 Nov; 129(5):1960-5. PubMed ID: 7119438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil aggregation induced by sera from patients with active systemic lupus erythematosus.
    Abramson SB; Given WP; Edelson HS; Weissmann G
    Arthritis Rheum; 1983 May; 26(5):630-6. PubMed ID: 6847725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The delayed appearance of an antinuclear factor and the diagnosis of systemic lupus erythematosus in glomerulonephritis.
    Cairns SA; Acheson EJ; Corbett CL; Dosa S; Mallick NP; Lawler W; Williams G
    Postgrad Med J; 1979 Oct; 55(648):723-7. PubMed ID: 317153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus.
    Miyawaki Y; Sada K; Asano Y; Hayashi K; Yamamura Y; Hiramatsu S; Ohashi K; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
    Lupus; 2018 Nov; 27(13):2093-2100. PubMed ID: 30309286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
    Lim KL; Jones AC; Brown NS; Powell RJ
    Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune complex deposits in systemic lupus erythematosus kidney without histological or functional alterations.
    Cruchaud A; Chenais F; Fournié GJ; Humair L; Lambert PH; Mulli JC; Chatelanat F
    Eur J Clin Invest; 1975 Jun; 5(3):297-309. PubMed ID: 1149788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological aspects of biopsy-proven lupus nephritis in Bahraini patients with systemic lupus erythematosus.
    Farid EM; Hassan AB; Abalkhail AA; El-Agroudy AE; Arrayed SA; Al-Ghareeb SM
    Saudi J Kidney Dis Transpl; 2013 Nov; 24(6):1271-9. PubMed ID: 24231503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The estimation of circulating immune complexes, C3d, and anti-ds-DNA-antibody serum levels in the monitoring of therapeutic plasmapheresis in a patient with systemic lupus erythematosus. A case report.
    Krapf F; Manger B; Koch B; Kraulledat P; Kalden JR
    Clin Exp Rheumatol; 1985; 3(2):159-62. PubMed ID: 3874738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group.
    Ricker DM; Hebert LA; Rohde R; Sedmak DD; Lewis EJ; Clough JD
    Am J Kidney Dis; 1991 Dec; 18(6):678-85. PubMed ID: 1962653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating immune complexes in lupus erythematosus, scleroderma and dermatomyositis.
    Sølling J; Sølling K; Jacobsen KU
    Acta Derm Venereol; 1979; 59(5):421-6. PubMed ID: 93365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients.
    Saisoong S; Eiam-Ong S; Hanvivatvong O
    Clin Exp Rheumatol; 2006; 24(1):51-8. PubMed ID: 16539819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.